Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Dapagliflozin
Treatment for Heart Failure
Typical Dosage: 10 mg once daily
Effectiveness
88%
Safety Score
65%
Clinical Trials
109
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg once daily
Time to Effect
1-2 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
21(Treat 21 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,500
Monitoring:$750
Side Effect Mgmt:$150
Total Annual:$7,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$18,500
Comparison vs Standard of Care
Cost Difference
+$6,500/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Dapagliflozin Outcomes
for Heart Failure
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+40%
Common Side Effects
Genital mycotic infections
+7%
Urinary tract infections
+5%
Hypotension
+2%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
7 active trials recruiting for Dapagliflozin in Heart Failure
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060RECRUITINGPHASE3
11.3K participants
INTERVENTIONAL
Birmingham, United States +941 more
Started: Mar 14, 2025
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure
NCT06578520RECRUITINGPHASE4
31 participants
INTERVENTIONAL
Valencia, Spain
Started: Jul 30, 2024
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
NCT05321706RECRUITINGPHASE3
430 participants
INTERVENTIONAL
Groningen, Netherlands +5 more
Started: Jun 8, 2022
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
NCT04707261RECRUITINGPHASE4
1.99K participants
INTERVENTIONAL
Xiangtan, China
Started: Aug 6, 2021
The Fontan Dapagliflozin Pilot Study
NCT05741658ENROLLING BY INVITATIONPHASE4
29 participants
INTERVENTIONAL
Los Angeles, United States
Started: Nov 8, 2023
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
NCT06304857RECRUITINGPHASE3
188 participants
INTERVENTIONAL
Wroclaw, Poland +2 more
Started: Apr 15, 2024
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714RECRUITINGPHASE1, PHASE2
60 participants
INTERVENTIONAL
Chicago, United States
Started: Jan 16, 2024
Completed Clinical Trials
7 completed trials for Dapagliflozin in Heart Failure
Dapagliflozin on Volume Vascular Outcomes.
NCT04869124COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Zurich, Switzerland
Started: Feb 15, 2021
Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
NCT04707352COMPLETEDPHASE3
162 participants
INTERVENTIONAL
Murcia, Spain
Started: Feb 8, 2021
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT04363697COMPLETEDPHASE4
2.4K participants
INTERVENTIONAL
Boston, United States
Started: Sep 24, 2020
Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
NCT04385589COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Aswān, Egypt
Started: May 1, 2020
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
NCT04249778COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Atlanta, United States +2 more
Started: Jul 29, 2020
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
NCT06065280COMPLETEDNA
80 participants
INTERVENTIONAL
Damanhūr, Egypt
Started: Nov 1, 2022
Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment
NCT04080518COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Singapore, Singapore
Started: Nov 11, 2019
Showing 20 of 124 total trials